Skip to main content

Daniel N. Dang, MD

Board Certifications

Anatomic and Clinical Pathology


Gastrointestinal Pathology, Hepatic Pathology




ProPath, a Sonic Healthcare anatomic pathology practice, is privileged to include Daniel N. Dang, M.D., as a part of its dynamic medical staff. Dr. Dang is a board-certified pathologist who brings professional medical and leadership experience to his position.

Dr. Dang graduated with a Bachelor of Science degree from Baylor University in Waco, Texas. He earned his medical degree at the University of Texas Medical Branch in Galveston. He served his residency in anatomic and clinical pathology from the University of Texas Southwestern Medical Center in Dallas, where he held the position of co-chief resident. He then completed a fellowship in gastrointestinal and liver pathology, also at UT Southwestern Medical Center.

Dr. Dang started as a staff pathologist at Southcentral Pathology in Wichita, Kansas. During this time, he held a clinical assistant professor appointment at the University of Kansas in Wichita. Prior to joining ProPath as a pathologist, Dr. Dang was also the medical director of laboratory at Ascension Via Christi St. Teresa Hospital in Wichita, KS, and Ascension Hospital in Wellington, KS.

Dr. Dang has peer-reviewed articles published in Human Pathology, Journal of Pediatric Hematology/Oncology, and Breast Cancer Management. He has also presented abstracts at meetings of the United States and Canadian Academy of Pathology, Texas Society of Pathologists, American Society for Clinical Pathology, and the College of American Pathologists.



Baylor University (BS)
Waco, TX

University of Texas Medical Branch (MD)
Galveston, TX


Postgraduate Training

Gastrointestinal and Liver Pathology Fellowship
University of Texas Southwestern Medical Center
Dallas, TX

Anatomic and Clinical Pathology Residency
University of Texas Southwestern Medical Center
Dallas, TX


Professional Memberships

College of American Pathologists

Medical Society of Sedgwick County


Peer-Reviewed Articles

  1. Dang DN, Raj G, Sarode V, Molberg KH, Vadlamudi RK, Peng Y. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1’s potential role in triple-negative breast carcinoma. Hum Pathol. 2015 Dec;46(12):1829-35.

  2. Dang DN, Morris HD, Feusner JH, Koduru P, Wilson K, Timmons CF, Cavalier M, Luu HS. Therapy-induced secondary acute myeloid leukemia with t(11;19)(q23;p13.1) in a pediatric patient with relapsed acute promyelocytic leukemia. J Pediatr Hematol Oncol. 2014 Nov;36(8):e546-8.

  3. Dang DN, Peng Y. Roles of p53 and p16 in triple-negative breast cancer. Breast Cancer Management. 2013;2(6):537-544.


  1. Dang DN. Ambiguous adenoma reporting leads to worse patient outcomes. USCAP Meeting, March 2017.

  2. Dang DN. Ambiguous adenoma reporting leads to worse patient outcomes [platform presentation]. Texas Society of Pathologists (Bastrop) Annual Meeting, January 2017.

  3. Dang DN. Significantly reduced E-cadherin protein expression (H-Score) in triple negative breast cancer and its correlation with Ki67. American Society for Clinical Pathology Meeting, October 2015.

  4. Dang DN. Comparison of PELP1 and GATA3 protein expression in triple-negative breast carcinoma: potential diagnostic utility in metastatic disease. USCAP Meeting, San Diego, CA, March 2014.

  5. Dang DN. Rare case of metaplastic carcinoma of the breast with exclusive sarcomatous metastasis and extensive mucinous metaplasia. CAP Meeting, Orlando, FL, October 2013.